Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RFA Combined with Gemcitabine and S-1 for Unresectable Cholangiocarcinoma
NCT05028439Completed
- Sponsor
- Hangzhou First People's Hospital
- Start
- Jan 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of gemcitabine and tegafur in cholangiocarcinoma (CCA) (2 arms), sponsored by Hangzhou First People's Hospital. Primary endpoint: Survival Time at 2 years. Started Jan 2020; status: completed.
02
Drugs
gemcitabinetegafur
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT05028439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05028439.